Mettler Toledo vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
Columbus OH precision instruments (NYSE: MTD) Q4 2024 revenue $1.045B (+12%), adjusted EPS $12.41 (+32%); global market leader lab balances and food inspection, pharma/biopharma lab destocking recovery competing with Sartorius.
About
Mettler-Toledo International Inc. is a Columbus, Ohio-based precision instruments and services company — publicly traded on the New York Stock Exchange (NYSE: MTD) as an S&P 500 Health Care component — manufacturing and marketing the world's most comprehensive range of weighing instruments and precision analytical measurement devices for laboratory, industrial, and food retail applications through approximately 18,000 employees in 40 countries. Mettler-Toledo's product portfolio spans laboratory balances and analytical instruments (used in pharmaceutical R&D and quality control), industrial scales and process analytics (used in chemical, food, and beverage manufacturing), pharmaceutical inspection systems (tablet and capsule inspection lines), food inspection equipment (X-ray and metal detection systems, checkweighers), and retail weighing solutions (supermarket scales). In Q4 2024, Mettler-Toledo reported revenue of $1.045 billion (+12% year-over-year) and adjusted EPS of $12.41 (+32% over the prior-year $9.40) — demonstrating the company's operational leverage as volume returned following the laboratory instruments market's destocking correction. CEO Patrick Kaltenbach has led Mettler-Toledo since 2020, maintaining the company's premium pricing strategy and capital return program (no dividend; all free cash flow directed to share repurchases that have reduced the share count by approximately 50% over the past decade). Mettler-Toledo operates as a category leader in precision weighing with 30%+ global market share and consistently achieves operating margins of 28-30%.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.